These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38926773)

  • 21. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
    Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
    J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
    Park MK; Ahn J; Kim YJ; Lee JW; Lee JC; Hwang SJ; Kim KC
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of Fully-Automated High-Throughput Plasma Biomarker Assays for Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subjects.
    Giuffrè GM; Quaranta D; Vita MG; Costantini EM; Citro S; Carrozza C; De Ninno G; Calabresi P; Marra C
    J Prev Alzheimers Dis; 2024; 11(4):1073-1078. PubMed ID: 39044519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
    Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
    Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform.
    Agnello L; Giglio RV; Del Ben F; Piccoli T; Colletti T; Scazzone C; Lo Sasso B; Ciaccio AM; Gambino CM; Salemi G; Ciaccio M
    Sci Rep; 2024 Jul; 14(1):16084. PubMed ID: 38992063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET.
    De Meyer S; Schaeverbeke JM; Luckett ES; Reinartz M; Blujdea ER; Cleynen I; Dupont P; Van Laere K; Vanbrabant J; Stoops E; Vanmechelen E; di Molfetta G; Zetterberg H; Ashton NJ; Teunissen CE; Poesen K; Vandenberghe R
    Brain Commun; 2024; 6(4):fcae162. PubMed ID: 39051027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease.
    Inekci D; Henriksen K; Linemann T; Karsdal MA; Habib A; Bisgaard C; Eriksen FB; Vilholm OJ
    Curr Alzheimer Res; 2015; 12(9):829-36. PubMed ID: 26159200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform.
    Martínez-Dubarbie F; Guerra-Ruiz A; López-García S; Lage C; Fernández-Matarrubia M; Infante J; Pozueta-Cantudo A; García-Martínez M; Corrales-Pardo A; Bravo M; López-Hoyos M; Irure-Ventura J; Sánchez-Juan P; García-Unzueta MT; Rodríguez-Rodríguez E
    Alzheimers Res Ther; 2023 Oct; 15(1):163. PubMed ID: 37784138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF Aβ
    Rizzi L; Missiaggia L; Roriz-Cruz M
    Neuromolecular Med; 2018 Dec; 20(4):491-497. PubMed ID: 30306396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology.
    Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I
    Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer's Disease.
    Lojo-Ramírez JA; Guerra-Gómez M; Marín-Cabañas AM; Fernández-Rodríguez P; Bernal Sánchez-Arjona M; Franco-Macías E; García-Solís D
    J Alzheimers Dis; 2024; 97(1):447-458. PubMed ID: 38143353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
    Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
    Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
    Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H;
    J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.